{"product_id":"medexus-business-model-canvas","title":"Medexus Pharma Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a pharma strategic playbook with our Business Model Canvas for investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Medexus Pharma’s strategic playbook with our Business Model Canvas — a concise map of its value propositions, customer segments, partnerships, and revenue drivers. Ideal for investors, consultants, and founders seeking actionable insights. Purchase the full, editable Canvas to benchmark, plan, and scale with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct licensors \u0026amp; innovators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartner with biotech and pharma originators to in-license or acquire rights to niche therapies, typically structuring co-promotion or exclusive North American distribution that together cover ~370 million people; many deals focus on territory rights and commercialization milestones. Access to pipeline and line-extensions sustains growth in markets where autoimmune conditions affect roughly 5–8% of the population, aligning portfolio to autoimmune, hematology and allergy specialties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers \u0026amp; packagers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUse GMP-certified CMOs\/packagers compliant with FDA and Health Canada requirements to ensure reliable supply across a combined U.S. and Canadian population of ~371 million (2024). Scale production regionally, secure redundancy via dual sourcing for critical SKUs to cut stockout risk, and enforce rigorous tech transfers and QC oversight throughout commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distributors \u0026amp; pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLeverage specialty distributors and specialty pharmacy networks for cold chain integrity and high-touch dispensing to ensure temperature-controlled delivery for biologics and injectables. Specialty medicines represented about 50% of US drug spending (IQVIA 2023), so these partners improve patient access and adherence in complex therapies. They enable utilization and outcomes data feedback and streamline reimbursement workflows, including prior authorization and hub services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOLs \u0026amp; clinical centers of excellence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with hematologists, rheumatologists and allergists who shape 2024 care guidelines accelerates appropriate adoption and informs lifecycle management through co-developed education and real-world evidence generation. This partnership model enhances credibility with prescribers and payers, supporting formulary access and targeted uptake in specialty clinics. Co-development of RWE supports reimbursement discussions and label optimization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEngage guideline KOLs\u003c\/li\u003e\n\u003cli\u003eCo-develop RWE \u0026amp; education\u003c\/li\u003e\n\u003cli\u003eDrive adoption \u0026amp; lifecycle\u003c\/li\u003e\n\u003cli\u003eBolster prescriber\/payer credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers, PBMs \u0026amp; public programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngage U.S. PBMs, private insurers and Canadian public drug plans—noting three PBMs manage roughly 80% of U.S. prescription claims—to negotiate coverage, formulary placement and reimbursement criteria for Medexus products.\u003c\/p\u003e\n\u003cp\u003eProvide robust health economics and outcomes evidence to support value and maintain ongoing outcomes reporting and outcomes-based contracting with payers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget partners: U.S. PBMs (~80% market), private insurers, provincial public plans\u003c\/li\u003e\n\u003cli\u003eGoals: formulary placement, reimbursement criteria, value-based contracts\u003c\/li\u003e\n\u003cli\u003eSupport: HEOR, real-world evidence, continuous outcomes reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn‑license autoimmune\/hematology for N.A. market \u003cstrong\u003e~371M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartner with biotech originators for in‑licensing and N.A. commercialization covering ~371M (2024); focus on autoimmune\/hematology\/allergy (prevalence 5–8%). Use GMP CMOs with dual sourcing to reduce stockouts. Rely on specialty distributors\/pharmacies and KOLs to drive uptake; engage PBMs (~3 firms cover ~80% US claims) and payers using HEOR\/RWE.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOriginators\u003c\/td\u003e\n\u003ctd\u003eIn‑license\/acquire\u003c\/td\u003e\n\u003ctd\u003ePipeline access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\/QA\u003c\/td\u003e\n\u003ctd\u003eDual sourcing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\/Payers\u003c\/td\u003e\n\u003ctd\u003eAccess\/reimbursement\u003c\/td\u003e\n\u003ctd\u003e~3 firms ≈80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Medexus Pharma detailing customer segments, channels, value propositions, key partners, and revenue streams tied to its specialty pharmaceutical strategy, with SWOT-linked insights for investors and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Medexus Pharma’s business model with editable cells that quickly highlight how the company alleviates commercialization, regulatory and supply-chain pain points for specialty therapies. Great for brainstorming, board discussions, or comparing strategic approaches across product portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-licensing \u0026amp; business development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSource, evaluate and negotiate rights to innovative and established products, leveraging due diligence and market modeling to de‑risk acquisitions. Focus on therapeutics addressing unmet needs in targeted specialties (oncology, rare disease, CNS) and structure deals with exclusivity windows and milestone\/royalty economics. Continuously refresh the pipeline through active BD; global biopharma partnering surpassed $100B in deal value in 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; pharmacovigilance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManage submissions, labeling and lifecycle updates across the U.S. (PDUFA standard review ~10 months in 2024) and Canada (standard review ~300 days; priority ~180 days), aligning provincial formulary requirements. Maintain safety systems to capture and report serious unexpected adverse events within FDA 15-day timelines and Health Canada requirements. Ensure full FDA, Health Canada and provincial compliance and coordinate with partners for CMC dossiers and variations, which can span weeks to months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs \u0026amp; education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedexus (TSX-V:MDX) deploys MSLs to engage KOLs for scientific exchange, prioritize peer-reviewed and real-world evidence generation to support adoption, and deliver CME plus disease-awareness initiatives to expand prescriber familiarity. Teams handle off-label inquiries through compliant medical information processes and documented escalation pathways. Activities align with 2024 regulatory and pharmacovigilance standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial execution \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRun field sales, key account management and contracting to secure formulary placement and hub services; specialty medicines accounted for over 50% of U.S. drug spending (CMS 2023), underscoring access importance. Deploy prior authorization templates, optimize pricing and value messaging by stakeholder, and track performance with rapid tactical adjustments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField sales \u0026amp; KAM\u003c\/li\u003e\n\u003cli\u003eContracting \u0026amp; formulary coverage\u003c\/li\u003e\n\u003cli\u003ePrior auth templates \u0026amp; hub services\u003c\/li\u003e\n\u003cli\u003ePricing optimization \u0026amp; value messaging\u003c\/li\u003e\n\u003cli\u003eReal-time performance tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain \u0026amp; quality management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedexus forecasts, plans and manages cross-border inventory to maintain 2–8°C cold chain integrity for temperature-sensitive drugs and ensures lot traceability per Health Canada Good Manufacturing Practices and record-keeping requirements. Regular audits and CAPAs with CMOs and distributors sustain compliance and quality; dual sourcing and safety stock policies mitigate shortages and reduce supply disruption risk. Real-time tracking and demand signals optimize replenishment across markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold chain range: 2–8°C\u003c\/li\u003e\n\u003cli\u003eRegulatory: Health Canada GMP lot traceability\u003c\/li\u003e\n\u003cli\u003eRisk controls: audits, CAPAs, dual sourcing\u003c\/li\u003e\n\u003cli\u003eInventory tools: real-time tracking, safety stock\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClose oncology\/rare\/CNS BD \u0026gt;$100B: fast US\/Canada approvals, formulary access, 2-8C cold chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSource and license oncology\/rare\/CNS assets; BD deals topped \u0026gt;$100B in 2024. Manage US (PDUFA ~10 months) and Canada (std ~300d; pri ~180d) submissions and safety reporting. Deploy MSLs, field sales\/KAM and contracting to secure formulary access; specialty drugs \u0026gt;50% US spend (CMS 2023). Maintain 2–8°C cold chain, dual sourcing and real-time tracking.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBD deals (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA\u003c\/td\u003e\n\u003ctd\u003e~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada std\/pri\u003c\/td\u003e\n\u003ctd\u003e~300d \/ ~180d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003e2–8°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Business Model Canvas previewed here is the exact Medexus Pharma document you’ll receive—this is not a mockup. When you purchase, you’ll get the full, editable file formatted the same way, ready for use in Word and Excel. No surprises—what you see is what you’ll own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth American commercial platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNorth American commercial platform with established sales, market access and distribution across the U.S. and Canada; deep relationships with hospitals, specialty pharmacies and national wholesalers enable rapid channel access. Proven cross-border regulatory and logistics expertise supports compliant product flow between jurisdictions. Infrastructure and field teams are scalable to onboard new products quickly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio rights \u0026amp; licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus leverages exclusive distribution and commercialization agreements in target disease areas with contractual protections and defined territories, typically covering North America and select EU markets. Data and registered trademarks underpin brand equity; trademarks are renewable every 10 years and data exclusivity windows vary by jurisdiction (typically 5–12 years). Licensing structures include option-to-license clauses for line extensions and new indications, tied to development milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical, regulatory \u0026amp; QA teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExperienced medical, regulatory and QA teams handle submissions and safety oversight, aligning with FDA PDUFA standard review targets of about 10 months for standard original NDAs. Field medical science liaisons provide scientific engagement and education to clinicians. Robust SOPs, GMP\/GCP-compliant quality systems and validated IT enable compliant operations. In-house capabilities support RWE generation and fulfillment of post-marketing commitments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData, CRM \u0026amp; analytics stack\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eData, CRM \u0026amp; analytics stack centralizes an integrated CRM for HCP engagement and account planning, ingests 2024 claims, specialty pharmacy and distribution feeds, and surfaces dashboards for demand, adherence and coverage to inform targeting, pricing and inventory decisions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated CRM for HCP targeting\u003c\/li\u003e\n\u003cli\u003eClaims, SP and distributor feeds\u003c\/li\u003e\n\u003cli\u003eDashboards: demand, adherence, coverage\u003c\/li\u003e\n\u003cli\u003eDrives pricing, targeting, inventory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner network \u0026amp; contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedexus (TSX:MDP in 2024) maintains long-term agreements with CMOs, distributors and payers that include multi-year volume commitments and service-level terms to secure supply continuity and margin predictability; pharmacovigilance frameworks comply with Health Canada and FDA expedited-reporting timelines (serious ADRs reported within 15 days) and GMP quality standards; legal contracts include indemnities, escrow and insurance layers to reduce operational risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO\/distributor multi-year contracts\u003c\/li\u003e\n\u003cli\u003eVolume commitments \u0026amp; SLA clauses\u003c\/li\u003e\n\u003cli\u003ePV frameworks: Health Canada\/FDA 15-day reporting\u003c\/li\u003e\n\u003cli\u003eLegal: indemnities, escrow, insurance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth American launch-ready: PDUFA ~\u003cstrong\u003e10\u003c\/strong\u003e months, \u003cstrong\u003e5–12\u003c\/strong\u003e yrs exclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNorth American commercial platform (U.S. and Canada) with scalable field teams and rapid channel access; PDUFA standard review ~10 months and data exclusivity typically 5–12 years. Multi-year CMO\/distributor contracts (commonly 3–5 years) with volume commitments and SLAs; PV frameworks meet Health Canada\/FDA 15-day serious ADR reporting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003eU.S. \u0026amp; Canada\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eReview\u003c\/td\u003e\n\u003ctd\u003ePDUFA ~10 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContracts\u003c\/td\u003e\n\u003ctd\u003eLength\u003c\/td\u003e\n\u003ctd\u003e3–5 yrs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFaster access to essential therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus rapidly brings needed treatments to patients across North America, leveraging its specialty-distribution footprint to reach clinics and hospitals serving rare-disease populations estimated at 300 million people worldwide. The company navigates regulatory and reimbursement pathways efficiently, using payer-engagement programs to shorten access timelines. By focusing on rare and specialty conditions with average diagnostic delays of 4.8 years, Medexus reduces time-to-therapy and supports physicians with streamlined onboarding and hub services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocused specialty expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus brings focused specialty expertise across autoimmune, hematology and allergy, addressing conditions that affect roughly 5% of the population. The company delivers tailored education and support to prescribers and operationalizes appropriate-use guidance shaped by KOLs and current evidence. This specialty approach is designed to enhance clinical confidence and improve patient outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-touch patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHub services assist with benefits verification, copay access, and adherence support, handling prior authorizations and appeals to simplify initiation. Personalized nursing, training, and automated refill reminders deliver tailored care and education. Industry data through 2024 show patient-support hubs can reduce prescription abandonment by up to 30% and boost persistence roughly 20%. These services lower access friction and speed therapy starts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable, compliant supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eReliable, compliant supply through quality-assured manufacturing and integrated cold chain logistics minimizes product loss and supports continuous patient access; the global cold chain market reached about USD 220 billion in 2024, underscoring scale and investment. Redundancy and safety stock strategies prevent shortages, while lot-level traceability and rapid recalls protect patients and payers, reinforcing provider trust and contracting leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuality-assured manufacturing\u003c\/li\u003e\n\u003cli\u003eCold chain logistics (global market ~USD 220B in 2024)\u003c\/li\u003e\n\u003cli\u003eRedundancy \u0026amp; safety stock\u003c\/li\u003e\n\u003cli\u003eLot-level traceability \u0026amp; responsive recalls\u003c\/li\u003e\n\u003cli\u003eBuilds trust with providers and payers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic value for payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValue dossiers and HEOR demonstrate measurable cost offsets and improved outcomes, aligning with payer goals as US health spending exceeded 18% of GDP in recent years. Contracting flexibility, including outcomes-based elements, enables shared-risk agreements tied to utilization and clinical results. Efficient site-of-care strategies shift care to lower-cost settings, reducing total cost of care while transparency on utilization and real-world performance supports contract administration and payer trust.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR-backed cost offsets\u003c\/li\u003e\n\u003cli\u003eOutcomes-based contracting\u003c\/li\u003e\n\u003cli\u003eSite-of-care cost reduction\u003c\/li\u003e\n\u003cli\u003eReal-world transparency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccelerating specialty therapy access: -30% abandonment, +20% persistence, cold-chain USD 220B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedexus accelerates specialty therapy access in North America, targeting rare-disease cohorts within a ~300M global pool and conditions affecting ~5% of people. Hub services cut abandonment ~30% and raise persistence ~20% (industry 2024). Cold-chain reliability taps a USD 220B market (2024) and supports outcomes-based contracting aligned with US health spend \u0026gt;18% GDP.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFigure\u003c\/th\u003e\n\u003cth\u003eSource\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease population\u003c\/td\u003e\n\u003ctd\u003e~300M\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty prevalence\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHub impact\u003c\/td\u003e\n\u003ctd\u003e-30% abandonment\/+20% persistence\u003c\/td\u003e\n\u003ctd\u003eIndustry 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market\u003c\/td\u003e\n\u003ctd\u003eUSD 220B\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS health spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;18% GDP\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated account management assigns key account managers to hospitals, integrated delivery networks, and specialty pharmacies, providing contracting support and regular performance reviews; they serve as the single escalation point and drive long-term strategic partnerships. As of 2024 there are roughly 6,090 US hospitals, underscoring the scale of institutional engagement required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient hub engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient hub engagement handles onboarding, benefits verification and financial assistance, reducing initiation barriers and accelerating start-of-therapy. Regular touchpoints sustain adherence—2024 IQVIA data show patient support programs can improve medication persistence by ~18%. Multichannel reminders and education (phone, SMS, portal, telehealth) maintain engagement. Real-time feedback loops report therapy status to prescribers for care coordination and escalation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical liaison support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical science liaisons deliver balanced, evidence-based scientific information to HCPs, supporting safe and effective use of Medexus therapies. They facilitate investigator-initiated studies and real-world evidence generation to strengthen product value and inform market access in 2024. MSLs systematically gather clinical insights to refine strategy and promotional materials. All interactions ensure compliant responses to unsolicited medical requests.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvider training \u0026amp; resources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProvider training \u0026amp; resources include dosing guides, administration tools and access kits, complemented by webinars and in‑service sessions for clinical staff; reimbursement toolkits and templates support claims processing, and all materials are maintained in line with current labeling and Medexus Pharma (TSX: MDP.TO) standards as of 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDosing guides\u003c\/li\u003e\n\u003cli\u003eAdmin tools \u0026amp; kits\u003c\/li\u003e\n\u003cli\u003eWebinars\/in‑service\u003c\/li\u003e\n\u003cli\u003eReimbursement toolkits\u003c\/li\u003e\n\u003cli\u003eLabel‑aligned updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-market safety communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedexus maintains proactive pharmacovigilance with expedited adverse event review aligned to ICH E2A timelines (serious unexpected events reported within 15 days) and delivers safety updates to clinicians and regulators to reinforce trust and compliance. Rapid field communication protocols activate within 24–72 hours during supply changes or shortages, with clear channels for AE reporting, medical inquiries and recall coordination.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH E2A: 15-day expedited SAE reporting\u003c\/li\u003e\n\u003cli\u003eRapid field alerts: 24–72 hours\u003c\/li\u003e\n\u003cli\u003eDedicated AE reporting lines and medical info\u003c\/li\u003e\n\u003cli\u003eStrengthens regulatory compliance and prescriber trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e~6,090 hospitals reach; patient hubs raise persistence ~18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey account managers cover ~6,090 US hospitals driving contracting and reviews. Patient hub services boost persistence ~18% (IQVIA 2024) via benefits verification and financial aid. MSLs support RWE and compliant medical engagement; pharmacovigilance adheres to ICH E2A 15-day SAE reporting and 24–72h field alerts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospitals\u003c\/td\u003e\n\u003ctd\u003e6,090 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient persistence lift\u003c\/td\u003e\n\u003ctd\u003e~18% (IQVIA 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAE reporting\u003c\/td\u003e\n\u003ctd\u003e15 days (ICH E2A)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField alerts\u003c\/td\u003e\n\u003ctd\u003e24–72 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus specialty pharmacy network distributes complex, monitored therapies that in 2024 represented over half of total drug spend; it coordinates benefits, prior authorization (industry denial rates ~25%) and home delivery to reduce initiation delays. Programs capture adherence and outcomes data (specialty adherence often \u0026gt;70%) and provide in-person and digital patient education at dispense to improve persistence and clinical results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers \u0026amp; hospital distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus leverages national wholesalers (top three distributors control ~85% of US pharma distribution) and GPO-aligned routes to access hospitals and clinics, managing tenders and contract pricing to secure formulary placement. Operations target timely fulfillment with industry-standard on-time-in-full service levels near 98% for critical products, supported by centralized inventory and rebate management to optimize cash flow and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField sales \u0026amp; KAM outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn-person detailing to specialists and institutions drives prescriptions while targeted call plans—shaped by CRM and real-world data—prioritize high-value prescribers; joint business planning with key accounts aligns budgets and formulary access; rapid field-to-HQ feedback shortens response cycles. IQVIA 2024: global pharma market ≈ $1.6 trillion, underscoring commercial impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms \u0026amp; portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital platforms and portals centralize provider portals with resources, reimbursement tools and ordering links, supporting Medexus commercial workflows; a 2024 pilot reported an 18% uplift in online orders and a 12% webinar-to-order conversion rate.\u003c\/p\u003e\n\u003cp\u003ePatient-facing sites enable onboarding and support while analytics refine engagement, reducing onboarding time by 9% in 2024 pilots and informing content prioritization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProvider portals: resources, reimbursement, ordering\u003c\/li\u003e\n\u003cli\u003eEngagement: webinars, e-detailing, compliant hubs\u003c\/li\u003e\n\u003cli\u003ePatient sites: onboarding\/support\u003c\/li\u003e\n\u003cli\u003eAnalytics: behavior-driven refinements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConferences \u0026amp; medical education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedexus leverages presence at specialty congresses and CME events to showcase therapies, support satellite symposia and poster presentations, and engage KOLs and payer stakeholders for formulary and reimbursement dialogue; conferences serve as a launchpad for new indications or products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChannels: congresses, CME, symposia, posters\u003c\/li\u003e\n\u003cli\u003eStakeholders: KOLs, payers, clinicians\u003c\/li\u003e\n\u003cli\u003ePurpose: awareness, data dissemination, reimbursement\u003c\/li\u003e\n\u003cli\u003eRole: launchpad for indications\/products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty network trims initiation delays, lifts adherence \u0026gt;70% and hits ~98% OTIF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedexus specialty network distributes complex therapies (\u0026gt;50% of drug spend in 2024), managing benefits\/prior auth (denial ≈25%) and home delivery to reduce initiation delays.\u003c\/p\u003e\n\u003cp\u003ePrograms capture adherence (\u0026gt;70% specialty) and outcomes; centralized inventory and GPO\/wholesaler routes (top-3 ≈85% distribution) support ~98% OTIF.\u003c\/p\u003e\n\u003cp\u003eDigital portals produced an 18% uplift in online orders and 12% webinar-to-order conversion in 2024 pilots.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share of spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior auth denial\u003c\/td\u003e\n\u003ctd\u003e≈25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTIF\u003c\/td\u003e\n\u003ctd\u003e~98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline order uplift\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHematologists, rheumatologists and allergists are the primary prescribers for Medexus specialty therapies and exert high influence on therapy selection and patient access. IQVIA 2024 shows specialty medicines account for over 50% of global medicine spending, underscoring the need for robust evidence and payer-facing data. These specialists require timely access, reliable supply chains and clinician-facing support tools, plus ongoing medical guidance to maintain prescribing confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals \u0026amp; infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSites administering complex infused therapies require contracting, cold-chain logistics, and clinical training; hospitals and infusion centers are highly sensitive to formulary and care-pathway decisions and prioritize operational efficiency and safety. In 2024, roughly 6,000 US hospitals and thousands of dedicated infusion suites drove site-of-care negotiations and throughput optimization, making streamlined supply, training, and compliance critical for Medexus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacies dispense Medexus high-touch therapies, handling drugs that represent about 55% of U.S. drug spend while accounting for under 2% of prescriptions (IQVIA 2024). They manage adherence, REMS (over 60 active programs per FDA) and regulatory reporting, directly shaping patient experience and outcomes. These partners require tight program coordination and secure bidirectional data exchange for monitoring and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and PBMs decide coverage, utilization management, and pricing for Medexus products, demanding clinical and economic evidence tied to outcomes and budget impact; in 2024 over 90% of payers applied utilization management for specialty therapies. They prioritize contracts and value propositions that demonstrate cost offsets, real-world effectiveness, and predictable budget impact to enable formulary placement and rebates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003etags: coverage\u003c\/li\u003e\n\u003cli\u003etags: utilization management\u003c\/li\u003e\n\u003cli\u003etags: pricing\u003c\/li\u003e\n\u003cli\u003etags: outcomes\u003c\/li\u003e\n\u003cli\u003etags: budget impact\u003c\/li\u003e\n\u003cli\u003etags: contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients \u0026amp; caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIndividuals living with autoimmune, hematologic, and allergic conditions need improved access, affordability and education; about 50 million Americans have autoimmune diseases (NIH) and medication nonadherence costs US healthcare $100–300 billion annually; targeted support programs and reminders can improve adherence and real-world outcomes by ~20% (2024 data).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient group: autoimmune, hematologic, allergic\u003c\/li\u003e\n\u003cli\u003eNeeds: access, affordability, education\u003c\/li\u003e\n\u003cli\u003eImpact: nonadherence $100–300B; adherence +~20%\u003c\/li\u003e\n\u003cli\u003eValue: support programs, reminders, outcome tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty meds \u003cstrong\u003e\u0026gt;50%\u003c\/strong\u003e spend; payers \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e use UM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHematologists, rheumatologists and allergists drive prescribing of Medexus specialty therapies; specialty medicines \u0026gt;50% of global medicine spend (IQVIA 2024). Hospitals\/infusion sites (~6,000 US hospitals, 2024) and specialty pharmacies (≈55% US drug spend; \u0026lt;2% of scripts) require cold-chain, REMS and training. Payers use utilization management in \u0026gt;90% of specialty therapies (2024), demanding real-world outcomes and budget impact.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescribers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% global spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e~6,000 US hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e55% spend, \u0026lt;2% scripts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% UM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of goods \u0026amp; manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayments to CMOs, API suppliers and packagers drive the bulk of COGS—industry ranges for specialty injectable players in 2024 put outsourced manufacturing at roughly 20–50% of product cost. Batch releases, stability testing and QA typically add 5–10% to per-batch costs. Cold-chain consumables and product wastage (1–3%) increase unit costs materially for biologics. Scale effects reduce per-unit COGS as volume rises, often nonlinearly after fixed-cost absorption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing \u0026amp; medical\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus cost structure concentrates on field force, KAMs and MSLs delivering segmented therapy-area campaigns and education, supported by promotional materials and congress spend. Digital platforms and analytics—now accounting for over 30% of commercial budgets in 2024—drive targeted multi-channel outreach and ROI measurement. Investments prioritize therapy-specific content and KOL engagement to maximize HCP adoption and formulary access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties \u0026amp; milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoyalties and milestone obligations to licensors are structured by sales tiers, triggering tiered royalty rates and performance milestones tied to approvals and sales thresholds. Agreements include upfront, development and regulatory milestone payments plus occasional minimum-guarantee clauses. These cash obligations create variability in gross margins as payments accelerate with revenue growth. This cost line is a material driver of Medexus’ product-level profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedexus regulatory and compliance costs cover submission fees (FDA NDA fee FY2024: 3,239,400 USD), validated PV systems, audits\/inspections, retained legal counsel and ongoing SOP maintenance, REMS\/risk-management program implementation, plus continuous training and quality systems supporting pharmacovigilance and inspection readiness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubmission fees: 3,239,400 USD (FDA FY2024)\u003c\/li\u003e\n\u003cli\u003ePV systems \u0026amp; audits: enterprise-scale annual ops\u003c\/li\u003e\n\u003cli\u003eLegal\/SOPs: continuous\u003c\/li\u003e\n\u003cli\u003eREMS \u0026amp; training: ongoing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLogistics \u0026amp; distribution costs for Medexus cover warehousing, freight and last-mile delivery, with the 2024 global pharmaceutical cold chain market valued at about USD 18.4 billion, driving higher temperature-controlled freight premiums and insurance. SP network fees and chargebacks commonly add 1–3% to net sales while inventory holding and obsolescence elevate carrying costs, often near 25% annualized for specialty drugs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWarehousing: temperature-controlled storage, insurance\u003c\/li\u003e\n\u003cli\u003eFreight\/last-mile: premium rates for cold chain\u003c\/li\u003e\n\u003cli\u003eSP fees\/chargebacks: 1–3% of sales\u003c\/li\u003e\n\u003cli\u003eInventory holding\/obsolescence: ~25% annual carrying cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u003cstrong\u003e20–50%\u003c\/strong\u003e of COGS; QA +5–10%; cold-chain $18.4B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOutsourced manufacturing drives 20–50% of COGS; QA\/stability add 5–10% and cold-chain waste 1–3%, with scale reducing unit cost nonlinearly. Commercial spend centers on field force\/MSLs and digital (≈30% of commercial budget in 2024). Royalties\/milestones and regulatory (FDA fee 3,239,400 USD FY2024) create variable cash outflows; inventory carrying ≈25% and SP fees 1–3% pressure margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Line\u003c\/th\u003e\n\u003cth\u003eKey Metric\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced manufacturing\u003c\/td\u003e\n\u003ctd\u003e20–50% of product cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQA\/Stability\u003c\/td\u003e\n\u003ctd\u003e+5–10% per batch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain market\u003c\/td\u003e\n\u003ctd\u003eUSD 18.4B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial digital\u003c\/td\u003e\n\u003ctd\u003e≈30% of budget (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA submission fee\u003c\/td\u003e\n\u003ctd\u003e3,239,400 USD (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory carrying\u003c\/td\u003e\n\u003ctd\u003e≈25% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSP fees\/chargebacks\u003c\/td\u003e\n\u003ctd\u003e1–3% of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales US \u0026amp; Canada\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet revenue from specialty and hospital products in US \u0026amp; Canada is the primary revenue engine, driven by demand, coverage, and pricing; seasonality and tender cycles can cause quarter-to-quarter variability. Coverage expansions and formulary placements materially influence realized net prices and patient uptake. Hospital tender timing often concentrates sales into specific quarters, amplifying revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicense \u0026amp; distribution fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLicense and distribution fees provide Medexus with upfront and territory access payments from partners, supplemented by service fees for commercialization activities such as marketing, regulatory support and supply chain management. Contracts often include minimum order commitments to secure baseline revenue and reduce partner risk. These fees diversify income beyond net product sales, smoothing cash flow and supporting pipeline investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones \u0026amp; contingent payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMilestones and contingent payments in Medexus Pharma deals are structured around regulatory, launch, and sales-triggered milestones within in-licensing and co-development agreements, delivering non-recurring cash inflows tied to achievement events. These payments mitigate upfront risk by linking payouts to regulatory approvals, commercial launches, and sales thresholds. They align incentives between Medexus and partners by sharing upside and focusing resources on milestone delivery. Such provisions are common in specialty-pharma partnership models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional contracts \u0026amp; tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional contracts and tenders with GPOs, hospitals and public procurements deliver predictable, volume-driven revenues for Medexus, typically via multi-year (1–3 year) agreements and strict, volume-based pricing terms. Competitive bidding stabilizes baseline utilization and often secures recurring shipments, supporting inventory planning and margin visibility. Public tenders also enhance market share through large single-award purchases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue source: GPOs, hospitals, public procurements\u003c\/li\u003e\n\u003cli\u003eContract terms: volume-based pricing, 1–3 year duration\u003c\/li\u003e\n\u003cli\u003eMarket effect: stable demand, competitive bidding\u003c\/li\u003e\n\u003cli\u003eOperational benefit: improves baseline utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-promotion \u0026amp; services income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-promotion and third-party services generate fee-based revenue for Medexus through upfront and ongoing sales support, supplemented by medical education grants and data services tied to product launches and real-world evidence programs. Outcome- or shared-savings arrangements align incentives with payers and providers, and the company monetizes platform capabilities (commercial analytics, digital engagement) to create recurring service income.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFee-for-service co-promotion\u003c\/li\u003e\n\u003cli\u003eMedical education grants \u0026amp; data services\u003c\/li\u003e\n\u003cli\u003eShared-savings \/ outcomes-based fees\u003c\/li\u003e\n\u003cli\u003ePlatform monetization: analytics \u0026amp; digital services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNet US\/Canada product sales anchor revenue; licenses, milestones and co-promotion diversify cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet product sales in US and Canada are the core revenue driver, with realized net prices shaped by payer coverage, formulary placement and hospital tender timing.\u003c\/p\u003e\n\u003cp\u003eLicense, distribution and service fees provide upfront and recurring cash, often with minimum order commitments to stabilize income.\u003c\/p\u003e\n\u003cp\u003eMilestones and contingent payments deliver non-recurring, event-driven inflows tied to regulatory and sales triggers.\u003c\/p\u003e\n\u003cp\u003eCo-promotion, outcomes-based fees and platform services diversify recurring revenue and align incentives with partners.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098308120924,"sku":"medexus-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/medexus-business-model-canvas.png?v=1781800716","url":"https:\/\/pestel-analysis.com\/products\/medexus-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}